Pharmacological risks of khat-oral antidiabetic drug interactions among patients...

연구 요약

Pharmacological risks of khat-oral antidiabetic drug interactions among patients at Gondar university referral hospital.

Scientific reports 학술지에 발표된 이 연구는 Mengesha AK, Ayele HS, Beyna AT 외 연구팀이 수행하였습니다.

이 연구는 'Pharmacological risks of khat-oral antidiabetic drug interactions among patients at Gondar university referral hospital.'에 대한 과학적 분석을 제공합니다.

핵심 내용

BACKGROUND: Khat (Catha edulis), a psychoactive plant commonly chewed in Ethiopia, is known to influence drug metabolism through its active compound, cathinone. Among patients with T2DM, concurrent khat chewing and OAD use may result in pharmacokinetic and pharmacodynamic interactions, particularly in polypharmacy contexts. Despite these concerns, the clinical relevance of khat-OAD interactions remains poorly understood in high-prevalence, low-resource settings. METHODS: This study assessed the prevalence, predictors, and perceptions of potential khat-OAD interactions among T2DM patients. A convergent parallel mixed-methods design was employed from July 1 to December 30, 2024, at Gondar University Hospital, Ethiopia. A total of 422 adult T2DM patients on OAD therapy who reported khat use were systematically sampled. Quantitative data on demographics, clinical profiles, medication use, and khat chewing behaviors were collected through structured interviews and verified via medical records. Potential interactions were identified using drug interaction databases, and logistic regression was used to determine independent predictors. Additionally, in-depth interviews with 20 patients and healthcare providers explored awareness, perceptions, and clinical experiences related to khat use and diabetes care. RESULTS: Among the 422 participants, 63.3% (n = 267) had at least one potential khat-OAD interaction, and 23.2% (n = 98) experienced a major interaction. The most frequently implicated drugs were glibenclamide and sitagliptin. Significant predictors of interaction included female sex (AOR = 1.38; 95% CI: 1.00-1.89), polypharmacy with ≥ 7 medications (AOR = 2.43; 95% CI: 1.61-3.67), daily khat use (AOR = 2.20; 95% CI: 1.52-3.18), and khat use for ≥ 13 years (AOR = 1.09; 95% CI: 1.04-1.15). Qualitative findings highlighted the widespread cultural normalization of khat chewing, low patient awareness of potential interactions, and gaps in provider counseling. CONCLUSIONS: Harmful khat-OAD interactions are common among T2DM patients in Northwest Ethiopia, primarily driven by behavioral and treatment-related factors, highlighting the need for culturally sensitive pharmacovigilance and patient education. CLINICAL TRIAL NUMBER: Not applicable.

일반인을 위한 해석

구체적인 실천 사항은 담당 의사 또는 약사와 상담하시기 바랍니다.

실천 사항

• 현재 복용 중인 약물이나 영양제에 대해 궁금한 점이 있다면 담당 의사 또는 약사와 상담하시기 바랍니다
• 약물이나 영양제의 용법·용량을 임의로 변경하지 마세요
• 이상 반응이 나타나면 즉시 전문가에게 문의하세요

의사/약사의 전문적 판단을 대체하지 않습니다 (PMID: 41266531)

📄 [전문 보기 (Markdown)](fulltext/41266531-pharmacological-risks-of-khat-oral-antidiabetic-drug-interac.md)